BeOne Medicines AG

NasdaqGS:ONC Stock Report

Market Cap: US$36.8b

BeOne Medicines Management

Management criteria checks 2/4

BeOne Medicines' CEO is John Oyler, appointed in Jan 2010, has a tenure of 15.83 years. total yearly compensation is $20.84M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 3.67% of the company’s shares, worth $1.35B. The average tenure of the management team and the board of directors is 3.5 years and 4.5 years respectively.

Key information

John Oyler

Chief executive officer

US$20.8m

Total compensation

CEO salary percentage5.28%
CEO tenure15.8yrs
CEO ownership3.7%
Management average tenure3.5yrs
Board average tenure4.5yrs

Recent management updates

Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why

May 15
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why

Recent updates

BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline

Oct 14

Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why

May 15
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
User avatar

US Facility And Phase III Trials Will Expand Markets

Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.

Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?

Apr 23
Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?

BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025

Feb 28

BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Feb 06
BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Is BeiGene (NASDAQ:ONC) A Risky Investment?

Jan 14
Is BeiGene (NASDAQ:ONC) A Risky Investment?

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

Dec 01

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

CEO Compensation Analysis

How has John Oyler's remuneration changed compared to BeOne Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$178m

Mar 31 2025n/an/a

-US$392m

Dec 31 2024US$21mUS$1m

-US$645m

Sep 30 2024n/an/a

-US$854m

Jun 30 2024n/an/a

-US$524m

Mar 31 2024n/an/a

-US$784m

Dec 31 2023US$19mUS$871k

-US$882m

Sep 30 2023n/an/a

-US$976m

Jun 30 2023n/an/a

-US$2b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$18mUS$800k

-US$2b

Sep 30 2022n/an/a

-US$2b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$17mUS$740k

-US$1b

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$14mUS$696k

-US$2b

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$1b

Mar 31 2020n/an/a

-US$1b

Dec 31 2019US$13mUS$675k

-US$949m

Sep 30 2019n/an/a

-US$829m

Jun 30 2019n/an/a

-US$665m

Mar 31 2019n/an/a

-US$737m

Dec 31 2018US$28mUS$650k

-US$674m

Compensation vs Market: John's total compensation ($USD20.84M) is above average for companies of similar size in the US market ($USD13.46M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Oyler (57 yo)

15.8yrs
Tenure
US$20,836,439
Compensation

Mr. John V. Oyler Co-Founded BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder15.8yrsUS$20.84m3.67%
$ 1.3b
Xiaobin Wu
President7.5yrsUS$11.14m0.065%
$ 23.8m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board15.8yrsUS$4.25m0.68%
$ 250.3m
Aaron Rosenberg
Chief Financial Officer1.3yrsUS$6.93m0.00099%
$ 364.1k
Chan Lee
General Counsel & Senior VP3.3yrsUS$4.68m0.016%
$ 5.7m
Wang Lai
Global Head of Research & Developmentno dataUS$7.40m0.11%
$ 41.8m
Titus Ball
VP & Chief Accounting Officer1.7yrsno data0.0051%
$ 1.9m
Marcello Damiani
Chief Technology Officerless than a yearno datano data
Liza Heapes
Head of Investor Relationsno datano datano data
Eleanor Duff
Senior VP & Head of Corporate Communicationsless than a yearno datano data
Mark Lanasa
Senior VP & Chief Medical Officer for Solid Tumors3.8yrsno datano data
Graham Hardiman
Global Head of Human Resources4.7yrsno datano data
3.5yrs
Average Tenure
56yo
Average Age

Experienced Management: ONC's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder15.1yrsUS$20.84m3.67%
$ 1.3b
Xiaodong Wang
Co-Chairman of Scientific Advisory Board9.8yrsUS$4.25m0.68%
$ 250.3m
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee10.6yrsUS$484.65k0.0044%
$ 1.6m
Corazon Sanders
Independent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee5.3yrsUS$502.40k0.0032%
$ 1.2m
Anthony Hooper
Chairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director5.8yrsUS$529.65k0.0038%
$ 1.4m
Neal Rosen
Member of Scientific Advisory Boardless than a yearno datano data
Charles Sawyers
Member of Scientific Advisory Boardless than a yearno datano data
David Schenkein
Member of Scientific Advisory Boardless than a yearno datano data
Shalini Sharp
Independent Non-Executive Director1.2yrsUS$303.07kno data
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director3.8yrsUS$494.65k0.0032%
$ 1.2m
Ranjeev Krishana
Member of Commercial & Medical Affairs Advisory Committee and Independent Lead Director11.1yrsUS$489.90k0.0044%
$ 1.6m
Margaret Han Dugan
Member of SA3.8yrsUS$514.90k0.0032%
$ 1.2m
4.5yrs
Average Tenure
65.5yo
Average Age

Experienced Board: ONC's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 22:24
End of Day Share Price 2025/11/07 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BeOne Medicines AG is covered by 64 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tianli WenAletheia Analyst Network Limited
Brian SkorneyBaird
Peter LawsonBarclays